CRA consultants were commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) to conduct an independent and objective assessment of the impact on the life sciences industry in Europe of a withdrawal of the United Kingdom from the European Union (commonly described as British exit from the EU or “Brexit”). The broad goal of this project was to identify, from both a UK and a European perspective, the positive and negative impact that a change in the relationship might have upon activities along the industry’s value chain.
To read the report, click the link below.
Women Leaders in Life Sciences Law 2025 review: Evolving litigation risks in the age of policy uncertainties
Attendees and panelists unpacked recent Executive Orders (EOs) in US legal responses and considered future implications for the life sciences sector. CRA’s...